{"doi":"10.1038/nrg.2016.93","title":"Targeting the cancer epigenome for therapy","abstract":null,"journal":"Nature Reviews Genetics","year":2016,"id":669701,"datarank":9.358144804177673,"base_score":7.049254841255837,"endowment":7.049254841255837,"self_citation_contribution":1.0573882261883758,"citation_network_contribution":8.300756577989297,"self_endowment_contribution":1.0573882261883758,"citer_contribution":8.300756577989297,"corpus_percentile":null,"corpus_rank":null,"citation_count":1151,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1749092,"name":"Jean-Pierre J. Issa","orcid":null,"position":1,"is_corresponding":false},{"id":69735,"name":"Stephen Baylin","orcid":null,"position":2,"is_corresponding":false},{"id":619292,"name":"Peter A. Jones","orcid":"0000-0001-8309-4767","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Targeting the cancer epigenome for therapy.","abstract":"Next-generation sequencing has revealed that more than 50% of human cancers harbour mutations in enzymes that are involved in chromatin organization. Tumour cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance. Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA). The future will see the increasing success of combining epigenetic drugs with other therapies. As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":25,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27629931","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"R01 CA082422","title":null},{"funder_name":"National Institutes of Health","grant_id":"5R37CA082422-13","title":"Mechanisms of De Novo Methylation in Cancer"},{"funder_name":"National Institutes of Health","grant_id":"3P50CA100632-06S1","title":"University of Texas M.D. Anderson Cancer Center SPORE - Leukemia"},{"funder_name":"National Institutes of Health","grant_id":"5R01CA158112-03","title":"Regulators of Cancer-Specific DNA Hypermethylation."},{"funder_name":"National Institutes of Health","grant_id":"5R01CA170550-02","title":"Epigenetic Drivers of Cancer (PQ 10)"}],"total_grants":5,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"Springer TDM","oa_locations":[{"url":"https://doi.org/10.1038/nrg.2016.93","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/27629931","host_type":""},{"url":"https://dx.doi.org/10.1038/nrg.2016.93","host_type":""}],"fields_of_study":["0301 basic medicine","0303 health sciences","03 medical and health sciences"],"mesh_terms":["Humans","Neoplasms","Histones","DNA Methylation","Epigenesis, Genetic","Histone Deacetylase Inhibitors","Epigenomics","High-Throughput Nucleotide Sequencing"],"keywords":["Epigenomics","Histone Deacetylase Inhibitors","Histones","Neoplasms","High-Throughput Nucleotide Sequencing","Humans","DNA Methylation","Epigenesis, Genetic"],"sdg_mappings":[{"sdg_number":2,"sdg_label":"2. Zero hunger"},{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.13579122.v1","title":"Additional file 1 of Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.13579122","title":"Additional file 1 of Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128573.v1","title":"Additional file 1 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128573","title":"Additional file 1 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128576.v1","title":"Additional file 2 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128576","title":"Additional file 2 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128579.v1","title":"Additional file 3 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15128579","title":"Additional file 3 of NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15179185.v1","title":"Additional file 1 of Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15179185","title":"Additional file 1 of Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15179188.v1","title":"Additional file 2 of Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15179188","title":"Additional file 2 of Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16683033.v1","title":"Additional file 1 of Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16683033","title":"Additional file 1 of Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17982794.v1","title":"Additional file 1 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17982794","title":"Additional file 1 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17982797.v1","title":"Additional file 2 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17982797","title":"Additional file 2 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612789.v1","title":"Additional file 12 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612789","title":"Additional file 12 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612792.v1","title":"Additional file 13 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612792","title":"Additional file 13 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612795.v1","title":"Additional file 14 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22612795","title":"Additional file 14 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22617827.v1","title":"Additional file 1 of BCL7A is silenced by hypermethylation to promote acute myeloid leukemia","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-15T02:29:34.964074Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}